ASCO GU 2025: Combination Therapy with Cabozantinib and Atezolizumab Shows Promise for Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxTransdermal Estradiol Patches Show Promise as a Safer Alternative to Traditional Hormone Therapy in Metastatic Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by MaxTalazoparib Plus Enzalutamide in HRR-Deficient mCRPC: Final Overall Survival Results from TALAPRO-2
/in Clinical Trial, Metastatic, Phase 3/by MaxASCO GU 2025: New Drug CBP-1018 Shows Promise for Advanced Prostate Cancer in Clinical Trial
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxUpdate Phase 1: Mevrometostat Shows Promise in Prostate Cancer by Targeting EZH2
/in Clinical Trial, Metastatic, Phase 1/by MaxPioneering Korean Trial Combines Radioligand Therapy and Immunotherapy for Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Clinical Trial Recruiting: HLD-0915 a RIPTAC (Regulated Induced Proximity Targeting Chimera)
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial Will Soon Start Recruiting: ACE-232 a Promising Inhibitor of CYP11A1
/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Biallelic Loss in DDR Genes and Its Clinical Impact July 25, 2026
- How DNA “Switches” in Prostate Cancer May Open New Treatment Paths July 25, 2026
- UPDATE: VIR-5500 Extended into mHSPC July 24, 2026
- UPDATE: SL-28 Phase 1/2 Trial Started To Recruit in Advanced Solid Tumors July 23, 2026